A centralized approach to tandem mass spectrometry method development for high-throughput ADME screening

Authors

  • Kevin Whalen,

    Corresponding author
    1. Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Eastern Point Rd., Groton, CT 06340, USA
    • Pfizer Global Research and Development, Groton Laboratories, MS 8118W-114, Pfizer Inc., Eastern Point Rd., Groton, CT 06340, USA.
    Search for more papers by this author
  • Jason Gobey,

    1. Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Eastern Point Rd., Groton, CT 06340, USA
    Search for more papers by this author
  • John Janiszewski

    1. Pfizer Global Research and Development, Groton Laboratories, Pfizer Inc., Eastern Point Rd., Groton, CT 06340, USA
    Search for more papers by this author

  • In honor of Dr. Robert Boyd, celebrating his distinguished tenure as Editor-in-Chief of Rapid Communications in Mass Spectrometry.

Abstract

A centralized approach to acquisition and dissemination of tandem mass spectrometry (MS/MS) conditions within an ADME-screening bioanalytical mass spectrometry group has been developed. The method development process uses two automated software products (Autoscan and Automaton) specifically designed for mass spectrometers manufactured by MDS Sciex. Both provide the ability to quickly determine selected reaction monitoring (SRM) transitions for hundreds of compounds per day. In addition, Autoscan determines optimal polarity and collision energy (CE). Automaton also determines the optimal declustering potential (DP) as well as the CE. The resulting optimized conditions are loaded into a central database for access by LC/MS/MS bioanalysis workstations in the group. The effect of DP and CE on the sensitivity was investigated. Optimization of DP improved signal response about 27% on average. For approximately 10% of compounds, signal enhancement was greater than 50% compared to the generic setting. A generic setting of DP = 25 V can be used for the majority of ADME-screening applications. Optimization of CE can have a much larger impact on signal intensity and a minimum of three CE settings should be tested. We have determined that CE values of 1, 30 and 45 V provide adequate coverage for most small molecule drug discovery analytes. Copyright © 2006 John Wiley & Sons, Ltd.

Ancillary